Blog Read the latest perspectives from our team of subject matter experts and others Your Provider Data Foundation for Compliance, Accuracy, and Member TrustHealth plans face relentless pressure to maintain accurate provider data amid intensifying regulatory scrutiny and compliance demands, where every error carries higher financial and reputational risk. Meanwhile, members demand seamless… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology Provider DataYour Provider Data Foundation for Compliance, Accuracy, and Member TrustHealth plans face relentless pressure to maintain accurate provider data amid intensifying regulatory scrutiny and compliance demands, where every error carries higher financial and reputational risk. Meanwhile, members demand seamless… Continue reading → Read the articleyes Artificial IntelligenceDrug DevelopmentThe AI Infrastructure Behind Modern Clinical TrialsClinical trial planning remains one of the most fragmented and manual processes in drug development. Sponsors often move between disconnected systems, static datasets, spreadsheets, and email threads to identify sites,… Continue reading → Read the articleno Drug DevelopmentIndustry-Leading H1 Support ServicesH1 offers sponsors unparalleled industry leading support services. The H1 Customer Success team stays embedded with sponsors long after they go live, helping partners realize value quickly, even if users… Continue reading → Read the articleno Artificial IntelligenceDrug DevelopmentAligning Incentives for Clinical Trials in the Age of AIAt SCOPE Summit US, Ariel Katz, CEO and Co-founder of H1, sat down with Robert Stevens, Head of Clinical Development Procurement at Bristol Myers Squibb, for a candid conversation about… Continue reading → Read the articleno Drug DevelopmentAI in Clinical TrialsAt Fierce JPM Week 2026, Ariel Katz, CEO and Co-founder of H1, sat down with Paul Bridges, PhD, President of Parexel’s Consulting organization, for a fireside chat that cut… Continue reading → Read the articleno Artificial IntelligenceDrug DevelopmentDrug Development Predictions 2026The drug development landscape is undergoing rapid transformation. After a year of significant policy changes, regulatory updates, and technology maturation, 2026 will be a defining year for how clinical… Continue reading → Read the articleno1234›»
